It looks as though Mylan NV will enjoy exclusivity for its EpiPen Auto-Injector (epinephrine) for the treatment of severe anaphylaxis into 2017 at a minimum now that Teva Pharmaceutical Industries Ltd.’s application for a generic copy has been pushed back by FDA.
Teva revealed in a Securities & Exchange Commission filing Feb. 29 that it received a complete response letter from FDA...